FARON PHARMACEUTICALS OY
Clinical-stage biopharmaceutical company developing immunotherapies for cancer.
FARN | IL
Overview
Corporate Details
- ISIN(s):
- FI4000153309
- LEI:
- 7437009H31TO1DC0EB42
- Country:
- Finland
- Address:
- Joukahaisenkatu 6, FI-20520 TURKU
- Website:
- https://faron.com/
- Sector:
- Manufacturing
Description
Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company pioneers macrophage-targeting therapies to leverage the patient's immune system, aiming to address unmet medical needs and improve outcomes. Its lead asset, bexmarilimab, is a first-in-class anti-Clever-1 antibody and a myeloid cell-targeting immunotherapy candidate. Bexmarilimab is being investigated in clinical trials as a potential therapy for hematological malignancies and solid tumors, often in combination with standard-of-care treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-20 08:00 |
Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement…
|
English | 17.4 KB | ||
| 2025-10-03 12:00 |
Faron Pharmaceuticals Ltd: Registration of New Shares
|
English | 7.5 KB | ||
| 2025-10-03 08:00 |
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rig…
|
English | 10.2 KB | ||
| 2025-09-19 08:00 |
Faron Pharmaceuticals Ltd: Exercise of Options, Director Dealing and Issue of E…
|
English | 26.4 KB | ||
| 2025-09-12 17:25 |
Correction: FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – …
|
English | 127.9 KB | ||
| 2025-08-27 08:00 |
FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025
|
English | 31.5 KB | ||
| 2025-08-19 08:00 |
Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results
|
English | 5.1 KB | ||
| 2025-08-18 08:00 |
Inside Information: Faron to advance bexmarilimab into a registrational Phase 2…
|
English | 13.5 KB | ||
| 2025-08-08 16:00 |
Faron Pharmaceuticals Ltd: Holding(s) in Company
|
English | 47.7 KB | ||
| 2025-08-08 09:30 |
Faron announces extension to its key patent family around bexmarilimab and targ…
|
English | 9.7 KB | ||
| 2025-08-07 08:00 |
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rig…
|
English | 10.1 KB | ||
| 2025-08-06 08:00 |
Inside Information: Faron to present updated BEXMAB data in frontline HR-MDS to…
|
English | 10.5 KB | ||
| 2025-07-30 08:30 |
FARON ANNOUNCES ACCEPTANCE OF BEXMARILIMAB DATA FOR ORAL PRESENTATION AT ESMO 2…
|
English | 13.3 KB | ||
| 2025-07-09 08:00 |
Faron announces acceptance of two studies involving bexmarilimab, one of them a…
|
English | 10.5 KB | ||
| 2025-07-02 12:00 |
Faron Pharmaceuticals Ltd: Director Dealing
|
English | 25.2 KB |
Automate Your Workflow. Get a real-time feed of all FARON PHARMACEUTICALS OY filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for FARON PHARMACEUTICALS OY
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for FARON PHARMACEUTICALS OY via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
